* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Quality assurance and guidelines for validation of next
Genomic imprinting wikipedia , lookup
Genetic testing wikipedia , lookup
Biology and consumer behaviour wikipedia , lookup
Pathogenomics wikipedia , lookup
Genetic engineering wikipedia , lookup
Gene therapy of the human retina wikipedia , lookup
Epigenetics of human development wikipedia , lookup
History of genetic engineering wikipedia , lookup
Therapeutic gene modulation wikipedia , lookup
Fetal origins hypothesis wikipedia , lookup
Gene desert wikipedia , lookup
Genome evolution wikipedia , lookup
Quantitative trait locus wikipedia , lookup
Gene nomenclature wikipedia , lookup
Gene expression programming wikipedia , lookup
Gene therapy wikipedia , lookup
Site-specific recombinase technology wikipedia , lookup
Nutriepigenomics wikipedia , lookup
Gene expression profiling wikipedia , lookup
Epigenetics of neurodegenerative diseases wikipedia , lookup
Neuronal ceroid lipofuscinosis wikipedia , lookup
Microevolution wikipedia , lookup
Artificial gene synthesis wikipedia , lookup
Genome (book) wikipedia , lookup
Quality assurance and guidelines for validation of next-generation sequencing tools Gert Matthijs Center for Human Genetics University of Leuven, Belgium - on behalf of EuroGentest - Genetic testing Molecular testing 1 disease 1 (single) mutation 1 disease 1 gene different diseases 1 (single) gene 1 disease few genes 1 disease 1 chromosomal anomaly (un)known defect karyotyping different diseases many genes different diseases different anomalies total genome Molecular cytogenetic testing Cytogenetics G. Matthijs 2011 Long QT syndrome ? LQT1 LQT2 LQT3 LQT4 LQT5 LQT6 LQT7 LQT8 LQT9 LQT10 LQT11 LQT12 LQT13 ATTGTACGTGATGACCAGTGGAAT ACCGTAAGGTAAAGTACCGTGTAC TTGGTTGGAACGTAGACTGAATGC CAACCCTGGTATTGGTGTCCCGTG TACAAGGTTAGTAATGTACCATTGA TTCCGTAATACGTGTGGCGCGTGC GTAACACACTGACTGACCATCCTG GTAGCTAGTCAAGTCGTAGCTGTC GTGACGTAACGTATATGACACACG TCAGTACGGTCAGTACACACATGC TGTGGTGCAGTACAGATACAGTAC AGATTAGCAGAAATGCAGATTTAGT ATTGTACGTGATGACCAGTGGAAT ACCGTAAGGTAAAGTACCGTGTAC TTGGTTGGAACGTAGACTGAATGC CAACCCTGGTATTGGTGTCCCGTG TACAAGGTTAGTAATGTACCATTGA TTCCGTAATACGTGTGGCGCGTGC GTAACACACTGACTGACCATCCTG GTAGCTAGTCAAGTCGTAGCTGTC GTGACGTAACGTATATGACACACG TCAGTACGGTCAGTACACACATGC TGTGGTGCAGTACAGATACAGTAC AGATTAGCAGAAATGCAGATTTAGT ATTGTACGTGATGACCAGTGGAAT ACCGTAAGGTAAAGTACCGTGTAC TTGGTTGGAACGTAGACTGAATGC CAACCCTGGTATTGGTGTCCCGTG TACAAGGTTAGTAATGTACCATTGA TTCCGTAATACGTGTGGCGCGTGC GTAACACACTGACTGACCATCCTG GTAGCTAGTCAAGTCGTAGCTGTC GTGACGTAACGTATATGACACACG TCAGTACGGTCAGTACACACATGC TGTGGTGCAGTACAGATACAGTAC AGATTAGCAGAAATGCAGATTTAGT K. Devriendt 2012 Next Generation Sequencing (NGS) work flow Targeted sequencing Exome Capture array Library Preparation Sequencing Variant Annotation Courtesy: Erika Souche 2013 Sequence Capture Demultiplexing Variant Filtering Amplification Mapping Report Variant Detection Illumina run quality control Cluster density Courtesy: Erika Souche 2013 Sample quality control Base quality score by position Courtesy: Erika Souche 2013 Mapping Courtesy: Erika Souche 2013 Diagnostics quality control Courtesy: Erika Souche 2013 Nat Biotechnology 20 (2012): 1033-36 Nex-StoCT (standardization of clinical testing) Nat Biotechnology 20 (2012): 1033-36 Nat Biotechnology 20 (2012): 1033-36 Research ≠ Diagnostics EuroGentest wants to build on these available documents and the work of others, and then comment or amend where necessary. * US: Nex-StoCT (CDC) Nat Biotechnology 20 (2012): 1033-36 * UK: Targeted NGS Guidelines (CMGS) * AUSTRALIA: Concept NGS Guidelines (MPS-WG) * THE NETHERLANDS: Concept NGS Guidelines (VKGL) * ESHG PPPC: Recommendations for WGS Draft - Discussed at EuroGentest expert meeting, February 2013 ISSUES of analytical VALIDATION Cfr. US Guidelines Platform verification: verify the performance specifications established by the manufacturer (e.g., accuracy, precision, etc. (FDA) Test & Bioinformatics pipeline validation: validate system performance characteristics (accuracy, precision, reportable range, reference range, analytical sensitivity, analytical specificity, and other performance characteristics, as applicable) for laboratory-developed tests (LDTs) (CLIA) Reportable range: areas of the targeted region that cannot be sequenced reliably and therefore are excluded from the reportable range Draft - Discussed at EuroGentest expert meeting, February 2013 ISSUES of DEVELOPMENT of the assays Cfr. Dutch Guidelines * Definition of diagnostic test * Aim of NGS * Analytical routing * Core gene list * Diagnostic yield Draft - Discussed at EuroGentest expert meeting, February 2013 DEFINITION OF A GENETIC TEST Published evidence for a disease gene to be included in NGS diagnostics (gene list) This reference has to be included in the labs bibliography Disease genes and mutations that are not amenable to NGS testing (trinucleotide repeat expansions, deletions, …) should not be tested by NGS only (include that information to clinician) Draft - Discussed at EuroGentest expert meeting, February 2013 AIM OF NGS - Is the test used to exclude a disease? - Is the test used to confirm a disease? Depending on this, the approach may differ, and also this will affect how the results will be reported Reporting of ‘uncertain variants’(UVs): no difference with the way UVs will be reported for NGS as compared to current practice Draft - Discussed at EuroGentest expert meeting, February 2013 CORE GENE LIST A ‘core gene’ is a disease gene that has to be genotyped completely because it contributes largely/importantly to the disease prevalence. * Other criteria may be: actionable, treatable… * This may include gene dosage analysis Core genes have to be outlined in the test description Core gene should be outlined in BPG and in CUGC Note: invite experts to generate those (minimal) lists There is an economical aspect in these considerations Draft - Discussed at EuroGentest expert meeting, February 2013 REPORTING, REPORT TO THE CLINICIAN Cfr. Australian guidelines Technical details Quality issues Interpretation (strong preference to only report the known or likely pathogenic variants) * Requirements: - figure showing the coverage - list of genes that were analysed * Re-contacting / Re-analysis Draft - Discussed at EuroGentest expert meeting, February 2013 DISTINCTION AND BORDERS BETWEEN RESEARCH AND DIAGNOSTICS Diagnostics is (published) evidence driven Diagnostic test for genes when there is a known relation between genotype and pathology Research is hypothesis driven Any further analysis should be subject to Ethical Board Review Question: where does evidence end? The professional has to decide what is evidence and what is not proven. Draft - Discussed at EuroGentest expert meeting, February 2013